Chest
Clinical InvestigationsASTHMALung Deposition of Hydrofluoroalkane-134a Beclomethasone Is Greater Than That of Chlorofluorocarbon Fluticasone and Chlorofluorocarbon Beclomethasone: A Cross-over Study in Healthy Volunteers
Section snippets
Subject Selection and Training
Men and women from 18 to 55 years of age, between 155 cm and 190 cm in height, and within 25% of normal body weight for their height and frame size were eligible for inclusion in the study. Subjects were required to have abstained from tobacco for at least 1 year and have a < 10-pack-year smoking history. Subjects were also required to have an FEV1 at the screening visit ≥ 90% of predicted normal. In addition, women were required to have a negative urine pregnancy test result and be using a
Study Subjects
Out of 16 subjects screened, 9 subjects (5 men and 4 women) enrolled in and completed the study. Mean FEV1 was 3.8 L (SD, 0.7 L; range, 2.7 to 4.8 L). Mean FEV1 percent predicted was 98.4% (SD, 8.4%; range, 90.2 to 113.3%). Data from the respiratory feedback device demonstrated that mean breath patterns were consistent between study days and that subjects achieved the target breath patterns (Table 1).
Radiolabeling Validation
Figure 1shows the radiolabeling validation results for HFA-BDP, CFC-BDP, and CFC-FP. The
Discussion
In this study, a larger proportion of inhaled HFA-BDP reached the lungs compared with CFC-FP and CFC-BDP. With HFA-BDP, 53% of the ex-actuator dose was deposited in the lungs compared with 12 to 13% for CFC-FP and only 4% for CFC-BDP. Additionally, less HFA-BDP impacted and remained in the oropharynx and was subsequently swallowed compared with CFC-FP and CFC-BDP. Furthermore, HFA-BDP appeared to be deposited evenly throughout the lungs, including the large, intermediate, and small airways,
References (28)
- et al.
Inflammation of small airways in asthma
J Allergy Clin Immunol
(1997) - et al.
A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers
Int J Pharm
(1999) Development of fluticasone propionate and comparison with other inhaled corticosteroids
J Allergy Clin Immunol
(1998)- et al.
Differences in lung bioavailability between different propellants for fluticasone propionate
Lancet
(1999) - et al.
Pharmaceutical transition to non-CFC pressurized metered dose inhalers
Respir Med
(2000) - et al.
Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant
J Allergy Clin Immunol
(1999) - et al.
Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma
Chest
(1999) - et al.
Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose
Respir Med
(1998) - et al.
Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol
Ann Allergy Asthma Immunol
(2001) The relative clinical effectiveness of HFA-BDP and fluticasone propionate in asthma
Respir Med
(2000)
A randomized, double-blind comparison of beclomethasone dipropionate extrafine aerosol and fluticasone propionate
Ann Allergy Asthma Immunol
Efficacy of HFA-beclomethasone dipropionate extrafine aerosol (800 microg/day) vs HFA-fluticasone propionate (1000 microg/day) in patients with asthma
Respir Med
Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less
Respir Med
Binding kinetics of fluticasone propionate to the human glucocorticoid receptor
Steroids
Cited by (211)
Small airways in asthma: From inflammation and pathophysiology to treatment response
2024, Respiratory MedicinePatient response to the management during the acute presentation of cough variant Asthma: Retrospective cohort study
2023, Saudi Journal of Biological SciencesMetered dose inhalers (MDIs)
2021, Inhaled Medicines: Optimizing Development through Integration of In Silico, In Vitro and In Vivo ApproachesBOEHRINGER INGELHEIM - Individual trajectories and therapeutic adjustments in COPD: good questions to ask in practice
2020, Revue des Maladies Respiratoires ActualitesDevelopment of human respiratory airway models: A review
2020, European Journal of Pharmaceutical Sciences
This study was sponsored by 3M Pharmaceuticals, St. Paul, MN.
Dr. Leach was an employee of 3M Pharmaceuticals from 1990 to 2000, during which time the study was conducted. He is no longer employed by 3M. Dr. Leach owned stock in 3M during that period of time and continues to hold a portion of that stock. Since 1993, Ms. Davidson has been an employee of 3M Pharmaceuticals and has owned stock in 3M. Dr. Hasselquist has been an employee of the University of Minnesota since October 1990 and was a paid consultant to 3M during the time the study was conducted. Dr. Hasselquist does not own any stock in 3M or have any other financial interest in the company. Dr. Boudreau was a paid consultant at 3M Pharmaceuticals during the time the study was conducted. Dr. Boudreau does not own any negotiable securities (eg, stocks) in 3M Corporation or its subsidiaries.